000 03983cam a22003735c 4500
999 _c76857
_d76857
001 76857
003 ES-MaUEC
005 20230208121741.0
007 cr nn 008mamaa
008 130909t2013 ne | s |||| 0|eng d
020 _a9789400771499
024 7 _a10.1007/978-94-007-7149-9
_2doi
040 _aES-MaUEC
_bspa
050 4 _aRC280.P7
_bP76 2013 EB
082 0 4 _a614.5999
245 0 0 _aProstate Cancer :
_bShifting from Morphology to Biology
_cedited by Stefania Staibano
260 _aDordrecht, Netherlands
_bSpringer
_c2013
300 _a1 recurso en línea (XVIII, 296 p.)
_b41 ilustraciones, 38 ilustraciones en color
336 _aTexto (visual)
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
505 0 _aForeword. Preface. List of contributors. I Clues to morphological diagnosis and prognosis evaluation.-Update on diagnostic criteria, on biopsy and surgical specimen: pre-invasive lesions, from epithelial cell hyperplasia to carcinoma in situ invasive carcinoma. First-line immunophenotyping of prostate diseases.- II Molecular pathology.- Molecular determinants of cancer-related inflammation.- Apoptosis and autophagy.- Androgen receptor and steroidogenesis pathways.- Neuroendocrine differentiation - role of somatostatin receptors (SSTRs) for diagnosis, prognosis, and therapy.- Metastatic dissemination.- Resistance to castration - resistance to drugs.- Crossroads of signaling pathways. III Genetic and Epigenetic Events in prostate cancer.- Gene polymorphisms.- Expression signature.- Mapping prostate cancer aggressiveness loci.- Epigenetic mechanisms: histone acetylation, DNA methylation, miRNA, chromatin modifiers. IV A modern approach to therapy of prostate cancer: targeting the deadly subset.-Molecular markers for patient selection and stratification: personalized prognostic predictive models.- Targeting tumor angiogenesis.- Efficacy of signal transduction inhibition in advanced prostate cancer.- Therapeutic targeting of the bone pre-metastatic niche.- Counteracting hypoxia in radio-resistant metastatic lesions.- "Synthetic lethality": molecular co-targeting to restore the DNA.- Repair mechanisms in prostate cancer cells concluding remarks. Index
520 3 _aThe aim of this book will be to contribute to the education of a new generation of experts in urology, molecular biology, pathology and oncology, offering them sufficient knowledge in basic and translational research to be fluency in the web of interacting networks playing a role in prostate cancer development, progression, metastasis and drug-resistance.The volume will cover the latest innovative researches in prostate cancer, with particular emphasis to the state-of-the-art analysis technologies that are essential for the accurate identification of molecular targets for disease diagnosis, molecular mechanisms of tumorigenesis, markers for susceptibility, molecular-based prognostic prevision, characterization of biomarkers of drug efficacy and drug resistance, validation of new therapeutics and diagnostics. Current advancements on the intersecting data concerning transcriptomes, proteomes, the molecular techniques referred as "omes", will be reported and discussed
650 7 _aPróstata
_xCáncer
_0comprobar BNE19901355947
_2embne
_9182337
700 1 _aStaibano, Stefania
_eeditor literario
_986209
_0Local
710 2 _aSpringerLink (Online service)
_0Local
_9106996
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-94-007-7149-9
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901 _ai9789400771499
907 _a.b12824756
_b10-10-17
_c01-10-14
942 _2lcc
_cLE
945 _aRC280.P7 P76 2013 EB
_g1
_ieBOOK
_j0
_lmae
_o-
_pEUR0.00
_q-
_r-
_sb
_t15
_u0
_v0
_w0
_x0
_y.i11553960
_z06-04-17
988 _aEBOOK, EBSPRINGER
998 _am
_a_alco
_a_vill
_b04-04-17
_cm
_dz
_ek
_feng
_gne
_h0